Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193139 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
A Phase 2 study of Hyperhidrosis, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 1
- Study location
NCT02193139 is a Phase 2 study of Hyperhidrosis that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 195 participants, above the 75-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (160% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02193139, a Phase 2 study of Hyperhidrosis, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG WL8713, 6 mg
- DRUG WL8713, 12 mg
- DRUG WL8713, 18 mg
- DRUG WL8713, 24 mg
Study Locations (1)
California
- Watson Clinical Site - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193139
The ClinicalTrials.gov registry entry for NCT02193139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 75-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (160% higher). The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperhidrosis appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02193139 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02193139 about?
NCT02193139 is a clinical study titled "Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis". This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.
What is the current status of trial NCT02193139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2013-12. Estimated completion is 2014-06.
What conditions does trial NCT02193139 study?
This clinical trial studies the following conditions: Hyperhidrosis.
What interventions are being tested in trial NCT02193139?
The interventions under investigation include: Placebo (DRUG), WL8713, 6 mg (DRUG), WL8713, 12 mg (DRUG), WL8713, 18 mg (DRUG), WL8713, 24 mg (DRUG).
Who is sponsoring clinical trial NCT02193139?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02193139 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperhidrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
COMPLETED · Phase 2
-
An Open Label Study for Palmar Hyperhydrosis
COMPLETED · Phase 2
-
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
Botulinum Toxin Therapy in Hidradenitis Suppurativa
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.